The trypanosomiases

WHO, 2002 Burri, 2003, Human African trypanosomiasis, 1303 Miles, 2003, American trypanosomiasis (Chagas disease), 1325 Herwaldt, 1999, Leishmaniasis, Lancet, 354, 1191, 10.1016/S0140-6736(98)10178-2 Stevens, 2001, The molecular evolution of Trypanosomatidae, Adv Parasitol, 48, 1, 10.1016/S0065-308X(01)48003-1 Stevens, 1999, The ancient and divergent origins of the human pathogenic trypanosomes, Trypanosoma brucei and T cruzi, Parasitology, 118, 107, 10.1017/S0031182098003473 Guhl, 2000, Chagas disease and human migration, Mem Inst Oswaldo Cruz, 95, 553, 10.1590/S0074-02762000000400018 Prata, 2001, Clinical and epidemiological aspects of Chagas disease, Lancet Infect Dis, 1, 92, 10.1016/S1473-3099(01)00065-2 Pepin, 2001, The epidemiology and control of human African trypanosomiasis, Adv Parasitol, 49, 71, 10.1016/S0065-308X(01)49038-5 MacLeod, 2001, The population genetics of Trypanosoma brucei and the origin of human infectivity, Philos Trans R Soc Lond B Biol Sci, 356, 1035, 10.1098/rstb.2001.0892 MacLeod, 2000, Minisatellite marker analysis of Trypanosoma brucei: reconciliation of clonal, panmictic, and epidemic population genetic structures, Proc Natl Acad Sci USA, 7, 13442, 10.1073/pnas.230434097 Gibson, 2002, Epidemiology and diagnosis of African trypanosomiasis using DNA probes, Trans R Soc Trop Med Hyg, 96, S141, 10.1016/S0035-9203(02)90066-0 Raper, 2001, Trypanosome lytic factors: novel mediators of human innate immunity, Curr Opin Microbiol, 4, 402, 10.1016/S1369-5274(00)00226-5 Raper, 2002, Natural immunity to human African trypanosomiasis: trypanosome lytic factors and the blood incubation infectivity test, Trans R Soc Trop Med Hyg, 96, S145, 10.1016/S0035-9203(02)90067-2 Hager, 1997, Mechanism of resistance of African trypanosomes to cytotoxic human HDL, Nature, 385, 823, 10.1038/385823a0 Vanhamme, 2003, Apolipoprotein L-I is the trypanosome lytic factor of human serum, Nature, 422, 83, 10.1038/nature01461 De Greef, 1989, A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense, Mol Biochem Parasitol, 36, 169, 10.1016/0166-6851(89)90189-8 Xong, 1998, A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense, Cell, 95, 839, 10.1016/S0092-8674(00)81706-7 Welburn, 2001, Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene, Lancet, 358, 2017, 10.1016/S0140-6736(01)07096-9 Cattand, 2001, Sleeping sickness surveillance: an essential step towards elimination, Trop Med Int Health, 6, 348, 10.1046/j.1365-3156.2001.00669.x Remme, 2002, Strategic emphases for tropical diseases research: a TDR perspective, Trends Parasitol, 18, 421, 10.1016/S1471-4922(02)02387-5 Pays, 1998, American human trypanosomiasis 90 years after its discovery by Carlos Chagas, I: epidemiology and control, Med Trop (Mars), 58, 391 Fernandes, 1998, Brazilian isolates of Trypanosoma cruzi from humans and triatomines classified into two lineages using mini-exon and ribosomal RNA sequences, Am J Trop Med Hyg, 58, 807, 10.4269/ajtmh.1998.58.807 Laurent, 1997, Impact of clonal evolution on the biological diversity of Trypanosoma cruzi, Parasitology, 114, 213, 10.1017/S0031182096008414 Gaunt, 2003, Mechanism of genetic exchange in American trypanosomes, Nature, 421, 936, 10.1038/nature01438 Borst, 1998, Surface receptors and transporters of Trypanosoma brucei., Annu Rev Microbiol, 52, 745, 10.1146/annurev.micro.52.1.745 Barry, 2001, Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite, Adv Parasitol, 49, 1, 10.1016/S0065-308X(01)49037-3 Borst, 2002, Antigenic variation and allelic exclusion, Cell, 109, 5, 10.1016/S0092-8674(02)00711-0 Reina-San-Martin, 2000, A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase, Nat Med, 6, 890, 10.1038/78651 Frasch, 2000, Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi., Parasitol Today, 16, 282, 10.1016/S0169-4758(00)01698-7 Acosta-Serrano, 2001, The mucin-like glycoprotein super-family of Trypanosoma cruzi: structure and biological roles, Mol Biochem Parasitol, 114, 143, 10.1016/S0166-6851(01)00245-6 Pollevick, 2000, Trypanosoma cruzi surface mucins with exposed variant epitopes, J Biol Chem, 275, 27671, 10.1074/jbc.M000253200 Almeida, 2000, Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents, EMBO J, 19, 1476, 10.1093/emboj/19.7.1476 Magez, 1998, The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors, J Immunol, 160, 1949, 10.4049/jimmunol.160.4.1949 Nyakundi, 2002, The relationships between intestinal damage and circulating endotoxins in experimental Trypanosoma brucei brucei infections, Parasitology, 124, 589, 10.1017/S0031182002001701 Stich, 2002, Human African trypanosomiasis, BMJ, 325, 203, 10.1136/bmj.325.7357.203 Stich, 2001, Trypanosomiases, Medicine, 29, 42, 10.1383/medc.29.5.42.28133 Dumas, 1998, Clinical aspects of human African trypanosomiasis, 215 WHO, 1998 Louis, 2001, Diagnosis of human African trypanosomiasis in 2001, Med Trop (Mars), 61, 340 Penchenier, 2000, Diagnosis of human trypanosomiasis, due to Trypanosoma brucei gambiense in central Africa, by the polymerase chain reaction, Trans R Soc Trop Med Hyg, 94, 392, 10.1016/S0035-9203(00)90116-0 Enanga, 2002, Sleeping sickness and the brain, Cell Mol Life Sci, 59, 845, 10.1007/s00018-002-8472-0 Pentreath, 1995, Trypanosomiasis and the nervous system: pathology and immunology, Trans R Soc Trop Med Hyg, 89, 9, 10.1016/0035-9203(95)90637-1 Poltera, 1985, Pathology of human African trypanosomiasis with reference to experimental African trypanosomiasis and infections of the central nervous system, Br Med Bull, 41, 169, 10.1093/oxfordjournals.bmb.a072045 Chimelli, 1997, Trypanosomiasis, Brain Pathol, 7, 599, 10.1111/j.1750-3639.1997.tb01077.x Buguet, 2001, The duality of sleeping sickness: focusing on sleep, Sleep Med Rev, 5, 139, 10.1053/smrv.2000.0130 Jauberteau, 1991, Galactocerebrosides are antigens for immunoglobulins in sera of an experimental model of trypanosomiasis in sheep, J Neurol Sci, 101, 82, 10.1016/0022-510X(91)90020-8 Rassi, 2000, Chagas heart disease, Clin Cardiol, 23, 883, 10.1002/clc.4960231205 Girones, 2003, Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both?, Trends Parasitol, 19, 19, 10.1016/S1471-4922(02)00006-5 Engman, 2002, Pathogenesis of Chagas heart disease: role of autoimmunity, Acta Trop, 81, 123, 10.1016/S0001-706X(01)00202-9 Soares, 2001, The pathogenesis of Chagas disease: when autoimmune and parasite-specific immune responses meet, An Acad Bras Cienc, 73, 547, 10.1590/S0001-37652001000400008 Leon, 2001, Autoimmunity in Chagas heart disease, Int J Parasitol, 31, 555, 10.1016/S0020-7519(01)00163-1 Tarleton, 2001, Parasite persistence in the aetiology of Chagas disease, Int J Parasitol, 31, 550, 10.1016/S0020-7519(01)00158-8 WHO, 2002 Marcon, 2002, Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies, Diagn Microbiol Infect Dis, 43, 39, 10.1016/S0732-8893(02)00366-8 Pepin, 1994, The treatment of human African trypanosomiasis, Adv Parasitol, 33, 1, 10.1016/S0065-308X(08)60410-8 Keiser, 2001, New drugs for the treatment of human African trypanosomiasis: research and development, Trends Parasitol, 17, 42, 10.1016/S1471-4922(00)01829-8 Burchmore, 2002, Chemotherapy of human African trypanosomiasis, Curr Pharm Des, 8, 256, 10.2174/1381612023396159 Legros, 2002, Treatment of human African trypanosomiasis: present situation and needs for research and development, Lancet Infect Dis, 2, 437, 10.1016/S1473-3099(02)00321-3 Urbina, 2002, Chemotherapy of Chagas disease, Curr Pharm Des, 8, 287, 10.2174/1381612023396177 Urbina, 2001, Specific treatment of Chagas disease: current status and new developments, Curr Opin Infect Dis, 14, 733, 10.1097/00001432-200112000-00012 Pepin, 1991, African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis, Trans R Soc Trop Med Hyg, 85, 222, 10.1016/0035-9203(91)90032-T Burri, 2000, Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial, Lancet, 355, 1419, 10.1016/S0140-6736(00)02141-3 Pepin, 2000, Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial, Bull World Health Organ, 78, 1284 Jennings, 1993, Combination chemotherapy of CNS trypanosomiasis, Acta Trop, 54, 205, 10.1016/0001-706X(93)90093-Q Jennings, 2002, Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen, Parasitol Int, 51, 381, 10.1016/S1383-5769(02)00044-2 Mpia, 2002, Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis, Trop Med Int Health, 7, 775, 10.1046/j.1365-3156.2002.00933.x Legros, 1999, Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda, Trans R Soc Trop Med Hyg, 93, 439, 10.1016/S0035-9203(99)90151-7 Brun, 2001, The phenomenon of treatment failures in human African trypanosomiasis, Trop Med Int Health, 6, 906, 10.1046/j.1365-3156.2001.00775.x Barrett, 1999, The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes, Parasitol Today, 15, 136, 10.1016/S0169-4758(99)01414-3 Trouiller, 2002, Drug development for neglected diseases: a deficient market and a public-health policy failure, Lancet, 359, 2188, 10.1016/S0140-6736(02)09096-7 Trouiller, 1999, Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts, Trop Med Int Health, 4, 412, 10.1046/j.1365-3156.1999.00420.x Etchegorry, 2001, Availability and affordability of treatment for human African trypanosomiasis, Trop Med Int Health, 6, 957, 10.1046/j.1365-3156.2001.00764.x Stich, 2003, Waking up to sleeping sickness, Trends Parasitol, 19, 195, 10.1016/S1471-4922(03)00055-2 de Andrade, 1996, Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection, Lancet, 348, 1407, 10.1016/S0140-6736(96)04128-1 Sosa Estani, 1998, Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease, Am J Trop Med Hyg, 59, 526, 10.4269/ajtmh.1998.59.526 Da Silva, 1999, Chagas disease surgery, Mem Inst Oswaldo Cruz, 94, 343, 10.1590/S0074-02761999000700067 Wang, 1995, Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis, Annu Rev Pharmacol Toxicol, 35, 93, 10.1146/annurev.pa.35.040195.000521 Croft, 1999, Pharmacological approaches to antitrypanosomal chemotherapy, Mem Inst Oswaldo Cruz, 94, 215, 10.1590/S0074-02761999000200017 Degrave, 2001, Parasite genome initiatives, Int J Parasitol, 31, 532, 10.1016/S0020-7519(01)00144-8 Kelly, 1995, Transfection of the African and American trypanosomes, Methods Mol Biol, 47, 349 Clayton, 1999, Genetic manipulation of kinetoplastida, Parasitol Today, 15, 72, 10.1016/S0169-4758(99)01498-2 LaCount, 2001, RNA interference in African trypanosomes, Protist, 152, 103, 10.1078/1434-4610-00047 Michels, 2000, Metabolic aspects of glycosomes in trypanosomatidae: new data and views, Parasitol Today, 16, 482, 10.1016/S0169-4758(00)01810-X Cazzulo, 1994, Intermediate metabolism in Trypanosoma cruzi, J Bioenerg Biomemb, 26, 157, 10.1007/BF00763064 Verlinde, 2001, Glycolysis as a target for the design of new anti-trypanosome drugs, Drug Resist Updat, 4, 50, 10.1054/drup.2000.0177 Lakhdar-Ghazal, 2002, Glycolysis and proteases as targets for the design of new anti-trypanosome drugs, Curr Top Med Chem, 2, 439, 10.2174/1568026024607472 Aronov, 1999, Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase, Proc Natl Acad Sci USA, 96, 4273, 10.1073/pnas.96.8.4273 Barrett, 1997, The pentose phosphate pathway and parasitic protozoa, Parasitol Today, 13, 11, 10.1016/S0169-4758(96)10075-2 Hannaert, 2003, Plant-like traits associated with metabolism of Trypanosoma parasites, Proc Natl Acad Sci USA, 100, 1067, 10.1073/pnas.0335769100 Barrett, 2002, Perspectives for new drugs against trypanosomiasis and leishmaniasis, Curr Top Med Chem, 2, 471, 10.2174/1568026024607427 Fairlamb, 1992, Metabolism and functions of trypanothione in the Kinetoplastida, Annu Rev Microbiol, 46, 695, 10.1146/annurev.mi.46.100192.003403 Schmidt, 2002, Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development, Curr Top Med Chem, 2, 1239, 10.2174/1568026023393048 Bacchi, 1980, Polyamine metabolism: a potential therapeutic target in trypanosomes, Science, 210, 332, 10.1126/science.6775372 Muller, 2001, Targeting polyamines of parasitic protozoa in chemotherapy, Trends Parasitol, 17, 242, 10.1016/S1471-4922(01)01908-0 Le Quesne, 1996, Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes, Biochem J, 316, 481, 10.1042/bj3160481 Urbina, 1997, Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites, Parasitology, 114, S91, 10.1017/S0031182097001194 Docampo, 2001, Recent developments in the chemotherapy of Chagas disease, Curr Pharmaceut Design, 7, 1157, 10.2174/1381612013397546 Paul, 2001, Fatty acid synthesis in African trypanosomes: a solution to the myristate mystery, Trends Parasitol, 17, 381, 10.1016/S1471-4922(01)01984-5 Buckner, 2000, Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei, J Biol Chem, 275, 21870, 10.1074/jbc.M000975200 Ali, 1999, The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria, Mol Biochem Parasitol, 104, 67, 10.1016/S0166-6851(99)00131-0 Troeberg, 1999, Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei, Exp Parasitol, 91, 349, 10.1006/expr.1998.4386 Cazzulo, 2002, Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas desease, Curr Top Med Chem, 2, 1261, 10.2174/1568026023392995 Caffrey, 2000, Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy, Curr Drug Targets, 1, 155, 10.2174/1389450003349290 Whitby, 2000, Structural basis for the activation of 20S proteasomes by 11S regulators, Nature, 408, 115, 10.1038/35040607 Hasne, 2000, Drug uptake via nutrient transporters in Trypanosoma brucei, J Appl Microbiol, 89, 697, 10.1046/j.1365-2672.2000.01168.x Ferguson, 1999, The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness, Biochim Biophys Acta, 1455, 327, 10.1016/S0925-4439(99)00058-7 Shapiro, 1995, The structure and replication of kinetoplast DNA, Annu Rev Microbiol, 49, 117, 10.1146/annurev.mi.49.100195.001001 Stuart, 1997, RNA editing in kinetoplastid protozoa, Microbiol Mol Biol Rev, 61, 105, 10.1128/.61.1.105-120.1997 Schnaufer, 2002, Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA, Int J Parasitol, 32, 1071, 10.1016/S0020-7519(02)00020-6 Vanhamme, 1995, Control of gene expression in trypanosomes, Microbiol Rev, 59, 223, 10.1128/MMBR.59.2.223-240.1995 Docampo, 2001, The acidocalcisome, Mol Biochem Parasitol, 114, 151, 10.1016/S0166-6851(01)00246-8 Rahmathullah, 1999, Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan, J Med Chem, 42, 3994, 10.1021/jm990237+ Rodriques Coura, 2002, A critical review on Chagas disease chemotherapy, Mem Inst Oswaldo Cruz, 97, 3, 10.1590/S0074-02762002000100001 Schofield, 2001, Trypanosomiasis control, Int J Parasitol, 31, 614, 10.1016/S0020-7519(01)00162-X Dias, 2002, The impact of Chagas disease control in Latin America: a review, Mem Inst Oswaldo Cruz, 97, 603, 10.1590/S0074-02762002000500002 Schofield, 1999, The Southern Cone Initiative against Chagas disease, Adv Parasitol, 42, 1, 10.1016/S0065-308X(08)60147-5 Allsopp, 2001, Options for vector control against trypanosomiasis in Africa, Trends Parasitol, 17, 15, 10.1016/S1471-4922(00)01828-6 Jannin, 2001, Control of human African trypanosomiasis: back to square one, Med Trop (Mars), 61, 437 Grant, 2001, Insecticides for tsetse and trypanosomiasis control: is the environmental risk acceptable?, Trends Parasitol, 17, 10, 10.1016/S1471-4922(00)01848-1 Hargrove, 2000, Insecticide-treated cattle for tsetse control: the power and the problems, Med Vet Entomol, 14, 123, 10.1046/j.1365-2915.2000.00226.x Vreysen, 2001, Principles of area-wide integrated tsetse fly control using the sterile insect technique, Med Trop (Mars), 61, 397 Glasgow, 1970, Control by hand-catching and traps, 456 Rogers, 2002, A response to the aim of eradicating tsetse from Africa, Trends Parasitol, 18, 534, 10.1016/S1471-4922(02)02422-4